Trupanion CEO Margaret Tooth sells $183,434 in stock

Trupanion CEO Margaret Tooth executed stock transactions on May 20, 2025, selling 4,000 shares at an average price of $45.8585 under a pre-established 10b5-1 trading plan while exercising options to acquire 4,000 shares at $8.93. This follows Trupanion's Q1 2025 results, which surpassed expectations with an EPS of -$0.03 and revenue of $342 million, a 12% year-over-year increase; the company's subsidiary also received approval to pay a $26 million dividend to the parent company, and full-year revenue guidance projects 14% growth.

Analysis

Trupanion, Inc. (NASDAQ:TRUP) recently reported strong Q1 2025 results, with revenue increasing 12% year-over-year to $342 million and earnings per share of -$0.03, both surpassing analyst expectations (forecasted EPS was -$0.05 and revenue $337.82 million). This performance is further supported by a significant rise in operating cash flow to $16 million, up from $2.4 million in the prior year, and an approved $26 million extraordinary dividend from its subsidiary, American Pet Insurance Company, to Trupanion, underscoring enhanced cash generation capabilities. The company's outlook remains positive, with full-year 2025 revenue guided to grow 14% at the midpoint to between $1.390 and $1.425 billion, and Q2 2025 revenue anticipated between $344 million and $350 million. CEO Margaret Tooth's recent sale of 4,000 shares at an average price of $45.8585 was executed under a pre-disclosed Rule 10b5-1 trading plan adopted in November 2024 for financial diversification and was accompanied by an exercise of stock options to acquire an equivalent number of shares at $8.93, leaving her with a direct holding of 118,784 shares. The company, which saw its stock return 57% over the past year and maintains a "GOOD" financial health score according to InvestingPro analysis, is currently trading below InvestingPro’s calculated Fair Value.

Key Decisions for Investors

• Investors should consider Trupanion's strong Q1 2025 financial results, including 12% year-over-year revenue growth and significantly improved operating cash flow, alongside positive FY2025 revenue guidance projecting 14% growth at the midpoint, as evidence of the company's operational strength.
• The CEO's stock transactions, executed under a pre-arranged Rule 10b5-1 plan for diversification and involving both a sale and an option exercise, should be viewed in the context of her substantial remaining stake and the stock's current valuation below InvestingPro's indicated fair value, despite a 57% return over the past year.
• Continued monitoring of Trupanion's ability to meet its revenue growth targets, sustain operating cash flow improvements, and effectively utilize the $26 million intercompany dividend will be crucial for assessing future performance and validating the current positive outlook.